APOC3 and familial chylomicronemia syndrome: One of the first anti-apoC-III agents that became available was volanesorsen (formerly ISIS 304801, ISIS-APOCIII-Rx), an ASO, which reduced TG levels by 76.5% and plasma apoC-III levels by 84.2% in patients with familial chylomicronemia syndrome (FCS).